CERo Therapeutics Holdings, Inc. (NASDAQ:CERO – Get Free Report) was the target of a significant increase in short interest in the month of October. As of October 31st, there was short interest totalling 1,600,000 shares, an increase of 262.4% from the October 15th total of 441,500 shares. Currently, 3.9% of the company’s shares are sold short. Based on an average daily volume of 30,810,000 shares, the short-interest ratio is presently 0.1 days.
CERo Therapeutics Stock Performance
Shares of NASDAQ CERO traded down $0.02 during trading hours on Thursday, hitting $0.19. 11,129,342 shares of the company traded hands, compared to its average volume of 15,177,358. CERo Therapeutics has a 12 month low of $0.06 and a 12 month high of $12.80. The company’s 50 day moving average price is $0.10 and its 200 day moving average price is $0.36.
CERo Therapeutics (NASDAQ:CERO – Get Free Report) last issued its earnings results on Wednesday, August 14th. The company reported ($0.33) EPS for the quarter.
About CERo Therapeutics
CERo Therapeutics Holdings, Inc, an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.
Featured Articles
- Five stocks we like better than CERo Therapeutics
- P/E Ratio Calculation: How to Assess Stocks
- 3 GARP Stocks Offering Strong Growth: Aptiv, Allstate, Barrick
- How to Use Stock Screeners to Find Stocks
- Mouse Rising: The Iger Investment Pays Off for Disney Investors
- Industrial Products Stocks Investing
- Can CAVA Stock Be the Next Chipotle? Earnings Can Help
Receive News & Ratings for CERo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CERo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
